GSNO Therapeutics

Executive Summary

GSNO Therapeutics is a preclinical-stage biotechnology company pioneering novel small molecule therapeutics targeting the S-nitrosoglutathione reductase (GSNOR) enzyme. Founded in 2018 and based in San Diego, the company's lead candidate, GTI-850, aims to restore S-nitrosylation homeostasis, a key regulatory mechanism disrupted in inflammation, fibrosis, autoimmunity, and oxidative stress. By inhibiting GSNOR, GTI-850 elevates endogenous S-nitrosoglutathione levels, potentially offering a broad therapeutic approach across multiple disease areas. The company is currently in the preclinical stage, with a focus on advancing GTI-850 toward investigational new drug (IND) enabling studies. GSNO Therapeutics represents a high-risk, high-reward investment opportunity, given its early stage and the translational challenges inherent in modulating a novel target. However, its platform addresses significant unmet medical needs and has the potential to be a first-in-class therapy if successfully developed.

Upcoming Catalysts (preview)

• Q4 2026IND-enabling study completion for GTI-85040% success
• Q3 2026Preclinical proof-of-concept data in fibrosis model55% success
• TBDPartnership or licensing agreement for GTI-85025% success